Please assess the completion status of the following clinical trial:

Trial Title: Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
* Inclusion Criteria:~  * at least 5 yrs since their last menses~ * Follicle Stimulating Hormone (FSH) \> 20 IU/L~* Exclusion Criteria:~  * Abnormality in any of the screening laboratory studies~ * Presence of significant liver or renal disease~ * Malignancy (including myeloma)~ * Malabsorption~ * Diabetes~ * Hypoparathyroidism~ * Hyperparathyroidism~ * Acromegaly~ * Cushing's syndrome~ * Hypopituitarism~ * Severe chronic obstructive pulmonary disease~ * Undergoing treatment with any medications that affect bone turnover, including the following:~* adrenocorticosteroids (\> 3 months at any time or \> 10 days within the previous yr)~* anticonvulsant therapy (within the previous year)~* pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal)~* calcium supplementation of \> 1200 mg/d (within the preceding 3 months)~* bisphosphonates (within the past 3 yrs)~* denosumab~* estrogen (E) therapy within the past year~* treatment with a selective E receptor modulator within the past year~* teriparatide within the past yr~* anti-hypertensive therapy~  * Clinical history of osteoporotic fracture (vertebral, hip, or distal forearm~ * Recent (within the past 6 months) fracture~ * Serum 25-hydroxyvitamin D levels of \< 20 ng/ml~ * Resting blood pressure \>140/90 mm Hg or those with hypotension (systolic blood pressure \<110 mm Hg), heart rate \< 60 bpm~ * History of asthma

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Sugar pill 2/day for 20 weeks; The once daily groups will receive a placebo as the second dose
- Atenolol (Type: ACTIVE_COMPARATOR): Atenolol 50 mg 1/day for 20 weeks
- Nebivolol (Type: ACTIVE_COMPARATOR): Nebivolol 5 mg/day for 20 weeks
- Propranolol 40 mg (Type: ACTIVE_COMPARATOR): Propranolol 20 mg bid for 20 weeks
- Propranolol 80 mg (Type: ACTIVE_COMPARATOR): Propranolol 40 mg bid for 20 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).